How to treat pathologic cell behaviors - Mark Cooper, PhD (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Jill Cottel, MD - Vitamin D and Autoimmune Disease: A Systematic Review of the Literature (2017 Conference) (LDN, low dose naltrexone)

Paul Anderson, NMD - Immune Therapies for Multiple Sclerosis (2017 Conference) (LDN, low dose naltrexone)

How LDN can be so successful in treating Multiple Sclerosis (MS) by boosting the immune system and improving the overall wellbeing of the patient.

Mark Cooper, PhD - LDN, Neuroinflammation, and Movement Disorders (2018 Conference) (LDN, low dose naltrexone)

Ted Cole, DO - The Use of LDN and Amino Acids in Parkinson's Disease (2019 Conference) (LDN, low dose naltrexone)

LDN 2019 Conference - Sunday Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Pamela Smith, MD - LDN and Multiple Sclerosis (2019 Conference) (LDN, low dose naltrexone)

Linda Elsegood - LDN, MS, The LDN Research Trust and Me (2019 Conference) (LDN, low dose naltrexone)

Linda Elsegood, Trustee of the LDN Research Trust, discusses why LDN isn’t widely prescribed, content on the LDN Research Trust website, The LDN Book, and what’s next for the Trust.

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)